Bridging Bio–Nano Science and Cancer Nanomedicine,ACS Nano

当前位置： X-MOL 学术 › ACS Nano › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Bridging Bio–Nano Science and Cancer Nanomedicine
ACS Nano ( IF 15.8 ) Pub Date : 2017-09-19 00:00:00 , DOI: 10.1021/acsnano.7b04855
Mattias Björnmalm ₁ , Kristofer J. Thurecht ₂ , Michael Michael _{3,

4} , Andrew M. Scott _{5,

6} , Frank Caruso ₁

Affiliation

The interface of bio–nano science and cancer medicine is an area experiencing much progress but also beset with controversy. Core concepts of the field—e.g., the enhanced permeability and retention (EPR) effect, tumor targeting and accumulation, and even the purpose of “nano” in cancer medicine—are hotly debated. In parallel, considerable advances in neighboring fields are occurring rapidly, including the recent progress of “immuno-oncology” and the fundamental impact it is having on our understanding and the clinical treatment of the group of diseases collectively known as cancer. Herein, we (i) revisit how cancer is commonly treated in the clinic and how this relates to nanomedicine; (ii) examine the ongoing debate on the relevance of the EPR effect and tumor targeting; (iii) highlight ways to improve the next-generation of nanomedicines; and (iv) discuss the emerging concept of working with (and not against) biology. While discussing these controversies, challenges, emerging concepts, and opportunities, we explore new directions for the field of cancer nanomedicine.

中文翻译：

桥接生物纳米科学与癌症纳米医学

生物纳米科学与癌症医学之间的联系是一个既有很大进步，又充满争议的领域。领域的核心概念，例如因此，人们对增强渗透性和保留（EPR）效果，肿瘤靶向和积累，甚至癌症医学中“纳米”的目的进行了激烈的辩论。同时，邻近领域的巨大进步也在迅速发生，包括“免疫肿瘤学”的最新进展及其对我们对统称为癌症的疾病组的理解和临床治疗产生的根本影响。本文中，我们（i）重新探讨了临床上通常如何治疗癌症以及癌症与纳米药物的关系；（ii）审查有关EPR效应与肿瘤靶向性相关性的正在进行的辩论；（iii）重点介绍改善下一代纳米药物的方法；（iv）讨论与（而不是反对）合作的新兴概念）生物学。在讨论这些争议，挑战，新兴概念和机遇的同时，我们探索了癌症纳米医学领域的新方向。

更新日期：2017-09-19

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11